An investigational immunotherapy was well tolerated and active in patients with acute lymphoblastic leukemia (ALL), a researcher said here.
In a small phase II study, the bi-specific antibody blinatumomab had an "exceptionally high response rate," said Max Topp, MD, of University Hospitals of Wuerzburg in Wuerzburg, Germany.
Over all doses, 72% of the study's 36 patients had a complete response or a hematological complete response within two cycles of treatment, Topp reported at the annual meeting of the American Society of Clinical Oncology. The proportion was slightly higher — 74% -- among the 23 patients who had the safest dose from the start.
Read the full story: http://hcp.lv/JLNsld
Source: MedPage Today